The corticostriatal and hippocampal circuits contribute to the neurobiological underpinnings of several neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease and schizophrenia. Based on biological function, these circuits can be clustered into motor circuits, associative/cognitive circuits and limbic circuits. Together, dysfunctions in these circuits produce the wide range of symptoms observed in related neuropsychiatric disorders. Intracellular signaling in these circuits is largely mediated through the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway with an additional role for the cyclic guanosine monophosphate (cGMP)/ protein kinase G (PKG) pathway, both of which can be regulated by phosphodiesterase inhibitors (PDE inhibitors). Through their effects on cAMP response element-binding protein (CREB) and Dopamine-and cAMP-Regulated PhosphoProtein MR 32 kDa (DARPP-32), cyclic nucleotide pathways are involved in synaptic transmission, neuron excitability, neuroplasticity and neuroprotection. In this clinical review, we provide an overview of the current clinical status, discuss the general mechanism of action of PDE inhibitors in relation to the corticostriatal and hippocampal circuits and consider several translational challenges.
1. Introduction
The corticostriatal circuits
The corticostriatal circuits are parallel organized circuits that run from the frontal cortex, through the basal ganglia, to the thalamus from where they project back to the frontal cortex, closing the circuits (Alexander et al., 1986; Alexander et al., 1990) . Therefore, corticostriatal circuits are also known as cortico-striatal-thalamic loops. The corticostriatal circuits consist of motor, associative/cognitive and limbic circuits (Alexander et al., 1986; Alexander et al., 1990) . Each circuit originates in a different part of the frontal cortex. Similarly, different nuclei of the basal ganglia and thalamus participate in these parallel circuits (Yeterian and Pandya, 1991; Slattery et al., 2001) . The different circuits are oriented dorsal to ventral and, even though they are called corticostriatal circuits, the ventral limbic circuits originate not only in the frontal cortex (medial orbitofrontal cortex and anterior cingulate cortex (ACC)) but also in the hippocampus and amygdala (Temel et al., 2005) . At least four circuits can be distinguished: the oculo-motor circuit (eye movement), motor circuit (motor functioning), dorsolateral prefrontal/lateral orbitofrontal circuit (cognitive functioning) and anterior cingulate/medial orbitofrontal circuit (emotion/ motivation).
The corticostriatal circuits start with efferent glutamatergic projections to the striatum (caudate nucleus, putamen and nucleus accumbens (NAc)). Within the basal ganglia all projections are γ-aminobutyric acid-ergic (GABA) except for output from the subthalamic nucleus (STN) which is glutamatergic. In the basal ganglia each corticostriatal circuit splits into a direct and an indirect pathway. Cortical glutamatergic activation of a striatal direct pathway stimulates the release of GABA, having an inhibitory effect in the globus pallidus pars interna (GPi) and substantia nigra pars reticulata (SNr). As the GPi and SNr inhibit the thalamus, which in turn stimulates the cortex, activation of the direct pathway causes disinhibition of the thalamus leading to increased excitatory output of the neural network, and thereby activation of behavior (either motor, cognitive or limbic). The indirect pathway has the opposite effect. Activation of the indirect pathway induces GABA release in the globus pallidus pars externa (GPe) which normally inhibits the release of GABA to the STN. The STN is thus disinhibited and increases stimulation of the GPi/SNr, which in turn inhibits the thalamic stimulation back to the cortex and results in inhibition of behavior. Additionally, the hyperdirect pathway consists of cortical glutamatergic projections to the STN, thereby completely circumventing the striatum. The activation of the STN increases glutamatergic excitation of the output nuclei of the basal ganglia circuits (GPi/SNr). Increased activation of the GPi/SNr results in increased release of GABA from the STN to the thalamus. This increased inhibition of the thalamus, results in inhibition of the thalamic stimulation to the cortex. In the end, activation of the hyperdirect pathways results in inhibition of behavior (see Fig. 1 ). Without cortical stimulation, the GPi and the SNr function like autonomous pacemakers, tonically inhibiting the thalamus, thereby preventing cortical stimulation, i.e. behavioral output (for a more extensive discussion see e.g. Haber and Rauch, 2010; Gerfen and Surmeier et al., 2011; Surmeier et al., 2011; Calabresi et al., 2014) . At the level of the basal ganglia the corticostriatal system is modulated by various GABAergic and cholinergic interneurons (Calabresi et al., 2014) . Additionally, every circuit is modulated by dopamine (Surmeier et al., 2007; Surmeier et al., 2011) . Dopaminergic cells from substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) project to almost every structure within the circuits (e.g. nigrostriatal, mesolimbic, mesocortical and thalamic dopamine projections). As a result, dopaminergic receptors are strongly expressed throughout the corticostriatal circuits (Gerfen and Surmeier et al., 2011; Nishi et al., 2011; Kuroiwa et al., 2012) . Unsurprisingly, dopaminergic medication has proven effective as treatment for several disorders related to dysfunctional corticostriatal circuits (e.g. attention deficit hyperactivity disorder (ADHD), schizophrenia, Parkinson's disease). Dopamine released from SNc and/or VTA binds to both dopamine type 1 (D1) receptors and type 2 (D2) receptors on medium spiny neurons (MSNs) in the striatum (Gerfen and Surmeier et al., 2011) . D1 receptors are mainly found on MSNs of the direct pathway and D2 receptors are mainly found on MSNs of the indirect pathway where they establish antagonistic interactions with adenosine A 2A receptors (Gerfen et al., 1990; Ferre et al., 2011) . D1 receptors activate the G s/olf family of G proteins to stimulate cyclic adenosine monophosphate (cAMP) production and thereby the direct pathway in the striatum (Sibley et al., 1993; Beaulieu and Gainetdinov, 2011) . In contrast, the D2 receptors couple to the G i/o family of G proteins and thus induce inhibition of cAMP production, thereby inhibiting the indirect pathway which eventually leads to disinhibition of the frontal cortex. Actions induced by dopamine receptor activation in both pathways can be viewed as synergistically or complementary.
Several neuropsychiatric disorders, including neurodegenerative disorders like Parkinson's disease and Huntington's disease, psychiatric illnesses such as schizophrenia, bipolar disorder and obsessive-compulsive disorder, and pervasive developmental disorders like ADHD and autism spectrum disorder, all share the corticostriatal circuits as their neurobiological basis (Alexander et al., 1986; Haber and Rauch, 2010; Gunaydin and Kreitzer, 2015) . Dysfunction of these circuits produces the wide range of motor, cognitive and affective symptoms observed in these neuropsychiatric disorders (Chudasama and Robbins, 2006 ).
Hippocampal circuits
The hippocampus is abundantly interconnected with the corticostriatal circuits providing input to the most ventral circuits, as mentioned above (Bonelli and Cummings, 2007) . Hence, when hippocampal neurodegeneration observed in Alzheimer's disease spreads to affect hippocampal neurons projecting to and from the corticostriatal circuits, corticostriatal symptoms will start emerging as is the case in, for example, advanced stages of Alzheimer's disease. Neurodegeneration of efferent hippocampal neurons to the corticostriatal circuits will cause corticostriatal neurons to become dysfunctional. Dysfunctional neurons in the corticostriatal circuits will induce corticostriatal system symptoms. However, due to the complexity of the hippocampal circuitry, it is mostly viewed as separate from the corticostriatal circuits. Therefore, in the current review we consider hippocampal circuitry as an independent neurobiological basis for disorders including Alzheimer's disease and depression as is further explained below.
The hippocampus is regarded as a central structure for learning and memory processes. It plays a crucial role in the encoding of new declarative information. Due to its extensive connections to prefrontal regions and the amygdala, it is assumed to play a prominent role in affective regulation as well (Charney et al., 2001 ). The hippocampus is a bilateral structure that resembles in form a seahorse and lies deep within the temporal lobes. It consists of four parts, namely the dentate gyrus, the cornu ammonis (CA), the presubiculum and the subiculum. The CA can be divided both anatomically and functionally into four parts: CA1, CA2, CA3 and CA4. The hippocampus is also described as having a ventral and a dorsal part (in animals) or an anterior and a posterior part (in humans) with similar composition, but both supporting different functions (Strange et al., 2014) . In rats the dorsal part seems mainly involved in locomotion, orientation of movement, spatial navigation, and exploration as well as learning and memory consolidation. The ventral part appears to be involved in limbic functions, motivated behavior, neuroendocrine functions and autonomic functions, thereby regulating the impact of emotional experiences and controlling general affective states (Fanselow and Dong, 2010) . Neurodegeneration of the hippocampus as observed in, for example, Hyperdirect, direct and indirect pathways of the corticostriatal circuit. Hyperdirect pathway: frontal cortex-STN-SNr/GPi-thalamus. Direct pathway: striatum-SNr/GPi-thalamus. Indirect pathway: striatum-GPe-STN-SNr/GPi-thalamus. STN = subthalamic nucleus, SNr = substantia nigra pars reticulata, GPi = globus pallidus pars interna, GPe = globus pallidus pars externa. Sharp arrow heads represent excitatory connections; blunted arrow heads represent inhibitory connections.
Alzheimer's disease or Huntington's disease, results in cognitive symptoms in the functional domains mentioned above. Patients often show problems such as memory loss, difficulty performing familiar tasks, problems with language, disorientation in time and space, problems with abstract thinking, misplacement of items, mood and personality changes, and loss of initiative.
The glutamatergic pyramidal cells in combination with the granule cells of the dentate gyrus constitute 90% of hippocampal neurons. The other neurons are mostly GABAergic interneurons. CA3 is characterized by a high density of glucocorticoids whereas CA1 also contains serotonin receptors. The hippocampus contains two very important pathways, the direct intrahippocampal pathway and the indirect afferent polysynaptic pathway (Campbell and Macqueen, 2004) . The former pathway connects the enthorinal cortex via CA1 to the subiculum. From the subiculum the pathway returns to the enthorinal cortex or splits of towards other cortical areas. The latter pathway connects the enthorinal cortex via the perforant path ('perforating' the subiculum) to the granule cells in the dentate gyrus. These cells, in turn, project via the mossy fibers to CA3. Axons of CA3 form the Schaffer collateral connecting to CA1 and even extending into the deep layers of the enthorinal cortex. CA1 constitutes the main cortical output of the hippocampus to other areas (Kempermann, 2006) .
The main modulatory projections to the hippocampus arise from the medial septal area (Cobb and Davies, 2005; Drever et al., 2011; TelesGrilo Ruivo and Mellor, 2013) . Medial septal cholinergic axons project to all regions of the hippocampus (Milner et al., 1983; Amaral and Kurz, 1985) , including CA1 and CA3 areas (Houser et al., 1983; Frotscher and Leranth, 1985; Matthews et al., 1987) , where they synapse on dendrites of pyramidal cells (Wainer et al., 1984) and dentate granule cells (Nyakas et al., 1987) . The localization of nicotinic and muscarinic acetylcholine receptor subtypes at both pre-and postsynaptic neurons enables the cholinergic system to exert its modulatory function on hippocampal circuitry. Integrating the functional contribution of fast nicotinic-and slower muscarinic-mediated responses allows acetylcholine to influence the dynamic properties of hippocampal networks over multiple timescales, creating optimal time windows for the induction of synaptic plasticity and resulting in the emergence of stable oscillatory ensembles, both of which play important roles in hippocampal information processing and memory formation (Teles-Grilo Ruivo and Mellor, 2013).
Phosphodiesterases
The need to develop strategies (e.g. pharmacotherapy, genetherapy, immunotherapy) that treat neuropsychiatric disorders is high since the accompanying symptoms and discomforts have a large impact on the quality of life of the patients and constitute a major burden to society. As a result, several strategies have been described targeting a wide range of domains. Research has focused on both environmental and genetic factors that cause neuronal dysfunction and death, or on enhancement of the ability of neurons to adapt (e.g. Mattson et al., 2002) . Despite the large effort that has been put in the development of these strategies, currently available treatments often show moderate efficacy at best and/or high rates of adverse events. Therefore, the need for strategies that counteract the detrimental processes involved in the decline of motor, cognitive and affective functioning (efficacy) with better side effect profiles (adverse events) remains high.
Last decades, phosphodiesterases (PDEs) are receiving increased attention as possible pharmacotherapeutic targets for treatment of disorders characterized by motor, cognitive and affective symptoms related to corticostriatal and hippocampal circuit dysfunction. A PDE inhibitor is a pharmacological compound blocking one or more of the subtypes of PDE (Bender and Beavo, 2006 )(see Table 1 ). There are eleven subfamilies of PDE comprising about 21 different genes each containing several splice variants and isoforms making up more than a hundred specific human PDEs (Bender and Beavo, 2006) each having a specific localization in the human body (Rentero et al., 2003; Wang et al., 2003; Esposito et al., 2009; Lakics et al., 2010) . PDEs degrade the second messengers cAMP and/or cyclic guanosine monophosphate (cGMP). PDE1, PDE2, PDE3, PDE10 and PDE11 are dual-substrate PDEs. PDE4, PDE7 and PDE8 are cAMP-specific, whereas PDE5, PDE6 and PDE9 are cGMP-specific (Beavo, 1995) .
With regard to cognition enhancement, initially, memory deficits as observed in Alzheimer's disease were the main focus of development of PDE inhibitors (e.g. Blokland et al., 2006; Heckman et al., 2015b; Wang et al., 2015; Prickaerts et al., 2017) . However, nowadays PDE inhibitors are also investigated as cognition enhancers in, for example, depression (e.g. Wong et al., 2006; Esposito et al., 2009; Zhang, 2009; Fujita et al., 2012; O'donnell and Xu et al., 2012) and schizophrenia (Menniti et al., 2007; Siuciak, 2008; Zhang, 2010; Duinen et al., 2015a,b; Heckman et al., 2015a) .
With regard to the development of PDE inhibitors as a potential treatment for motor dysfunctions, Parkinson's disease (Belmaker et al., 1978; Volicer et al., 1986; Nishino et al., 1993; Sancesario et al., 2004) and Huntington's disease (DeMarch et al., 2007; DeMarch et al., 2008; Puerta et al., 2010; Fusco and Giampa, 2015; Beaumont et al., 2016) are the main disorders of interest. Additionally, cyclic nucleotide regulation by PDE inhibitors has been related to tardive dyskinesia induced by antipsychotic treatment, or levodopa-induced dyskinesias (LIDs) (Sasaki et al., 1995; Yamashita et al., 1997a,b; Sharma et al., 2013; Wilson and Brandon, 2015) .
Finally, PDE inhibitors have also been linked to affect and emotion in disorders like depression, schizophrenia (negative symptoms) and anxiety disorders (Brink et al., 2008; Schmidt et al., 2008; Zinn et al., 2009; Reierson et al., 2011; Smith et al., 2013; Ding et al., 2014; Rutter et al., 2014; Plattner et al., 2015; Zhang et al., 2015) .
Phosphodiesterase signaling in the corticostriatal circuits
Intracellularly, direct and indirect pathway signaling in the striatum is largely mediated through the cAMP/PKA cascade (Nishi et al., 2008; Nishi and Snyder, 2010; Nishi et al., 2011; Fig. 2) . Cyclic nucleotide cascades are involved in synaptic transmission, neuron excitability, neuroplasticity and neuroprotection in both corticostriatal circuits as well as hippocampal circuitry (Heckman et al., 2016; Heckman et al., 2015b) . In the corticostriatal circuits, activation of these pathways can induce changes in synaptic transmission via increased presynaptic neurotransmitter release. This might be mediated via a presynaptic Ca 2+ /calmodulin-dependent protein kinase (CaMK)/cAMP/cAMP-dependent protein kinase (PKA) cascade and elevation of cAMP has been P.R.A. Heckman et al. Neuroscience and Biobehavioral Reviews 87 (2018) 233-254 found to result in the synthesis and/or release of several neurotransmitters including two main players in the corticostriatal circuits: glutamate and dopamine (Schoffelmeer et al., 1985; Imanishi et al., 1997; Rodriguez-Moreno and Sihra, 2013) . Next to enhanced presynaptic neurotransmitter release, a shortlasting form of postsynaptic neuroplasticity mediated by cyclic nucleotides is the membrane insertion (trafficking) of stored proteins, like ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. The latter occurs through activation of postsynaptic PKA by cAMP produced by adenylate cyclase (AC) stimulated by either glutamatergic-induced Ca 2+ influx or dopamine receptor-stimulated G s .
To induce longer-lasting forms of postsynaptic strengthening, PKA can result in the activation of two subsequent pathways: the cAMP response element binding protein (CREB) pathway (Mayr and Montminy, 2001 ) and the Dopamine-and cAMP-Regulated PhosphoProtein MR 32 kDa (DARPP-32) pathway (Greengard, 2001; Svenningsson et al., 2004) . In the first pathway, glutamate-or dopamine-activated PKA subsequently results in phosphorylation of CREB (pCREB). pCREB is an activated transcription factor, which initiates transcription of specific plasticity-related genes. The latter include genes for production of neurotransmitter receptors such as ionotropic AMPA receptors (Carew and Sutton, 2001; Izquierdo et al., 2006) or growth factors such as brain-derived neurotrophic factor (BDNF) (Scott Bitner, 2012) . After release, the protein BDNF binds to the tropomyosin-related kinase B (TrkB) receptor, which is the receptor with the highest affinity for BDNF, ultimately resulting in neuroprotection (Impey et al., 1996; Lu et al., 1999; Sakamoto et al., 2011; see Fig. 3 ).
The dopamine receptor/cAMP/PKA/DARPP-32 cascade constitutes the second pathway. DARPP-32 is phosphorylated at Thr34 in both striatal and frontal neurons converting into a potent inhibitor of protein (caption on next page) P.R.A. Heckman et al. Neuroscience and Biobehavioral Reviews 87 (2018) 233-254 phosphatase-1 (PP-1), whereas phosphorylation at Thr75 by Cdk5 converts DARPP-32 into an inhibitor of PKA. DARPP-32 has therefore the unique property of being a dual-function protein, acting either as an inhibitor of PP-1 or PKA, stimulating or inhibiting cascades involved in neuroplasticity, respectively (Svenningsson et al., 2004; Nishi and Shuto 2017) . The inhibition of PP-1 controls the phosphorylation state and activity of many downstream physiological effectors, including various neurotransmitter receptors (e.g. AMPA receptor GluR1 subunit, N-methyl-D-aspartate (NMDA) receptor NR1 subunit), ion channels and pumps (e.g. N/P-type Ca 2+ channels, Na + channel, Na
and transcription factors (e.g. CREB, c-Fos, ΔFosB) (Greengard et al., 1999; Song et al., 2013) . Although research unraveling the mechanisms of long-term potentiation (LTP) and neuroplasticity is mainly focused on memory and the hippocampus, these mechanisms also occur in brain structures of the corticostriatal circuits, like the striatum, frontal cortex and amygdala through cyclic nucleotide pathways (e.g. Calabresi et al., 1992; Lovinger and Tyler, 1996; Maren, 1996; Arnsten et al., 2005; Girault, 2012; Selemon, 2013) . In general, LTP and long-term depression (LTD) are considered the main constructs that persistently increase or decrease synaptic strength of neuronal connections, whether these connections represent motor programs, memories or emotional salience of an experience.
In addition to the backbone formed by MSNs and their dopaminergic modulation, the importance of interneurons in physiological and pathological corticostriatal functioning is becoming increasingly apparent. Several types of interneurons can be found in the striatum, like cholinergic and different GABAergic interneurons (Gerfen and Surmeier et al., 2011) . In particular, nitric oxide synthase (NOS) containing GABAergic interneurons we would like to highlight. In mammals, 3 different genetic loci have been characterized giving rise to 3 isoenzymes for NOS: i) the neuronal form (nNOS) or type I that is widely expressed in the brain, ii) the inducible form (iNOS) or type II that is present is astrocytes, microglial cells, smooth cells and macrophages and is produced in response to inflammation or trauma, iii) and the endothelial form (eNOS) or type III expressed in the endothelial cells of the central nervous system (CNS) and the periphery. The GABAergic interneurons thus contain nNOS. These nitric oxide (NO)-producing interneurons play an important role in corticostriatal functioning (West and Tseng, 2011) . NO diffuses into dendrites of MSNs which contain high levels of guanylate cyclase (GC), which, when activated, lead to the synthesis of cGMP (see Fig. 2 ). In the intact striatum, transient Fig. 2 . Effects of PDE inhibition in corticostriatal circuitry. Corticostriatal circuits originate in the frontal cortex, pass through the basal ganglia, which project via the thalamus back to frontal brain areas. Output neurons in the striatum are medium spiny neurons (MSNs), which consist of direct pathway and indirect pathway neurons. The direct pathway neurons inhibit tonically active neurons in globus pallidus interna (GPi)/substantia nigra pars reticulata (SNr). The indirect pathway neurons activate neurons in GPi/SNr via inhibition of the globus pallidus externa (GPe) and activation of the subthalamic nucleus (STN). Direct and indirect pathway neurons induce opposing effects on the output neurons in GPi/SNr, resulting in dis-inhibition and pro-inhibition of output, respectively. Within the basal ganglia all projections are GABAergic except those from the STN. Main phosphodiesterases (PDEs) expressed in corticostriatal circuits are PDE1B, PDE4 and PDE10A. PDE1B is generally co-localized with dopamine D1 receptors in the brain and thought to represent a major inactivation mechanism of D1 receptors. By acting like a dopamine agonist PDE1B inhibitors can enhance phosphorylation of cAMP response element binding protein (CREB) as well as Dopamine-and cAMP-Regulated PhosphoProtein MR 32 kDa (DARPP-32) enhancing synaptic transmission (e.g. AMPA receptors), neuron excitability, and synapto-and neurogenesis resulting in neuroplasticity and neuroprotective effects at glutamatergic frontal and corticostriatal synapses. Regarding corticostriatal signaling, the effect of PDE4 inhibition on cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling is linked to indirect pathway adenosine A2a receptor signaling and has no major role in D1 receptor direct pathway signaling. An opposite situation is observed at frontal dopaminergic signaling. In the frontal cortex PDE4 is -just as PDE1B-localized at DARPP-32 expressing neurons. In contrast to the striatum, PDE4 inhibition enhances dopamine D1 receptor-induced phosphorylation of DARPP-32 in the frontal cortex, indicating a prominent role of PDE4 in frontal dopamine receptor signaling. Finally, dopamine release from dopaminergic midbrain terminals can be influenced with a PDE4 inhibitor as dopamine is expressed at dopaminergic terminals in neurons of the substantia nigra pars compacta (SNc) in which cAMP has been reported to be a strong inducer of tyrosine hydroxylase gene transcription rate and mRNA affecting dopamine synthesis and release. In direct pathway neurons, PDE10A inhibition activates cAMP/PKA signaling related to D1 receptor signaling whereas in indirect pathway neurons PDE10A inhibition activates cAMP/ PKA signaling by simultaneous potentiation of adenosine A2A receptor signaling and inhibition of D2 receptor signaling. Effects of PDE10A inhibition predominate the indirect pathway. In contrast to PDE4 inhibition, PDE10A inhibition does not increase tyrosine hydroxylase phosphorylation and therefore has no effects on dopamine synthesis and release. Nevertheless, it cannot be ruled out that selective PDE inhibitors might influence both the direct and indirect pathway via enhancing the release of dopamine from frontal dopaminergic projections depending on the -to be determined-presence of PDEs in these terminals. In striatal interneurons containing nitric oxide synthase (NOS), nitric oxide (NO) is produced and diffuses into dendrites of MSNs which contain high levels of guanylate cyclase (GC), which, when activated, lead to the synthesis of cyclic guanosine monophosphate (cGMP). In the striatum, transient elevations in intracellular cGMP -next to cAMP-primarily act to increase neuronal excitability and to facilitate glutamatergic corticostriatal transmission. Thus, inhibition of selective PDE subtypes can also target the cGMP/protein kinase G (PKG) pathway and have an effect on corticostriatal functioning (Heckman et al., 2016 ; reprinted with permission). The cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) activated effectors are depicted over time. Elevation of cAMP has been found to result in the synthesis and/or release of several neurotransmitters (NT) including glutamate, dopamine and acetylcholine (red line). Subsequently, PKA can induce the insertion of stored neurotransmitter receptors such as ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (green line; initial increase) followed by the phosphorylation of cAMP response element binding protein (CREB; pCREB). pCREB is an activated transcription factor, which initiates transcription of specific genes which can include AMPA receptors (green line; secondary increase) or growth factors as brain-derived neurotrophic factor (BDNF; blue line). BDNF increases synaptic strength with adjacent neurons by processes like long-term potentiation (LTP), thus ameliorating their connectivity. LTP itself has been linked to both synaptogenesis (yellow line) and neurogenesis (purple line).
elevations in intracellular cGMP primarily act to increase neuronal excitability and to facilitate glutamatergic corticostriatal transmission (West and Tseng, 2011; Threlfell and West, 2013) . Although the main focus in the corticostriatal system has been on cAMP signaling, several PDE inhibitors (also) target cGMP and may exert their effects largely dependent on the cGMP signaling cascade (Padovan-Neto et al., 2015) . Finally, corticostriatal circuits contain abundant feedback, feedforward and cross-talk connections. The circuits form afferent and efferent connections with other cortical, subcortical and brain stem nuclei.
Phosphodiesterase signaling in the hippocampal circuits
Traditionally, the postsynaptic cAMP second messenger system (G s and G i linked) and the phosphoinositol second messenger system (G q linked) received most attention. The second messenger cAMP is synthesised by AC, which is stimulated or inhibited by G s or G i , respectively. The second messenger complex inositol-1,4,5,triphosphate/diacylglycerol (IP 3 /DAG) is formed out of the hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP 2 ) by phospholipase C (PLC) after activation by G q .
cAMP activates cAMP-dependent PKA, which phosphorylates CREB (see Fig. 4 ). pCREB is an activated transcription factor, which initiates transcription of specific genes which can include ionotropic AMPA receptors or growth factors as BDNF (Scott Bitner, 2012 (Sweatt, 1999) . In addition, CaMK can activate PKC, but also PKA via activation of AC and subsequent production of cAMP. In addition, PKA can also activate the MAP kinase pathway. Thus, there is interplay between the cAMP second messenger system and the phosphoinositol second messenger system. The enzyme AC is also present presynaptically and elevation of cAMP has been found to result in the synthesis and/or release of several neurotransmitters including glutamate and acetylcholine (Colquhoun and Patrick, 1997; Imanishi et al., 1997; Rodriguez-Moreno and Sihra, 2013) . This might be mediated via a presynaptic CaMK/cAMP/PKA cascade and thus signal transduction is influenced.
A comparable function as described for cAMP applies to the second messenger cGMP. Postsynaptically, Ca 2+ is known to activate the enzyme nNOS which produces NO (Murad et al., 1978) . The latter stimulates the enzyme GC which produces the second messenger cGMP. Cyclic GMP activates cGMP-dependent protein kinase (PKG), which can also induce CREB phosphorylation and affect several other targets (Lu et al., 1999) . In addition, NO also acts as a retrograde messenger stimulating presynaptic GC. Via a cGMP/PKG cascade the synthesis and/ or release of neurotransmitters, including glutamate and acetylcholine, can be influenced (Arancio et al., 1995; Colquhoun and Patrick, 1997) , and thus signal transduction. Recently, it has been demonstrated that for hippocampal-dependent memory formation cGMP/PKG signaling may require cAMP/PKA-signaling (Bollen et al., 2014 ).
Phosphodiesterase signaling and expression in disease
In addition to their well-known function as activators of PKA and PKG, cyclic nucleotides bind to cyclic nucleotide-gated channels (CNGCs) and 'exchange factor directly activated by cAMP' 1 and 2 (EPAC1 and EPAC2) (Keravis and Lugnier, 2012) . Because the activities of several of these effectors can be altered simultaneously in response to increases in cellular cAMP or cGMP, PDE inhibitors can activate several cellular signaling events that yield a series of finely-tuned 'read-outs' and allow crosstalk between cyclic nucleotides and other signaling networks and systems that markedly affect the numerous cellular processes (Dodge-Kafka et al., 2005; Mongillo et al., 2006; Houslay et al., 2007; Stangherlin et al., 2011; Wilson et al., 2011; Kritzer et al., 2012; Conti and Beavo, 2007; Francis et al., 2011) . The integration of Schematic diagram of pre-and postsynaptic cellular processes related to the second messengers cAMP and cGMP involved in LTP-related signal transduction in the hippocampus. Presynaptically, both the cAMP and cGMP cascades can induce enhanced neurotransmitter release. Postsynaptically, both cascades activate the CREB signaling pathway resulting in increased synaptic transmission, neuron excitability, neuroplasticity and neuroprotection. Abbreviations: PDE = phosphodiesterase; Ca 2+ =calcium; CaMK=calmodulin-dependent protein kinase; NOS = nitric oxide synthase; NO = nitric oxide; GC = guanylate cyclase; GTP = guanosine triphosphate; cGMP = cyclic guanosine monophosphate; PKG = protein kinase G; AC = adenylate cyclase; ATP = adenosine triphosphate; cAMP = cyclic adenosine monophosphate; PKA = protein kinase A; CREB = cAMP response element binding protein; NMDA= N-methyl-Daspartate; nAChR = nicotinic acetylcholine receptors (α4β2 and α7); mAChR = metabotropic acetylcholine receptor (M1, M3, M5).
individual PDEs into specific groups of proteins involved in the regulation of protein function, so called signalosomes, within regionallyrestricted, subcellular compartments of neurons of both the corticostriatal as well as the hippocampal circuitry, determines the functional roles of these individual PDEs and their respective isoforms, and thereby their therapeutic indication (Jurevicius and Fischmeister, 1996; Zaccolo et al., 2000; Mongillo et al., 2006; Maurice, 2011; Stangherlin et al., 2011; Stangherlin and Zaccolo, 2012) . In the corticostriatal and hippocampal circuits, the main cellular processes regulated by PDE inhibitors are believed to be those related to neuroplasticity and neuroprotection via an abundance of their downstream effectors. The stimulation of neuroplasticity and neuroprotection is considered to be the main therapeutic mechanism of action of PDE inhibitors in the corticostriatal and hippocampal circuits. However, known effects of PDE inhibitors on signaling mechanisms involved in neurodegeneration, neuroinflammation and cytokine-mediated responses may play additional roles, as well as cerebrovascular, brain oxygenation, glucose metabolism and free radical scavenging properties, yet are outside the scope of the present review Wilson and Brandon, 2015) .
All cGMP-and cAMP-specific PDEs are expressed in the human CNS including the corticostriatal areas and the hippocampus (Lakics et al., 2010) . Increased PDE activity is assumed to reduce cyclic nucleotide signaling in pathways important for brain plasticity and neuroprotection and is therefore considered to be causal, while a decrease in PDE activity might be considered as compensatory (Bollen and Prickaerts, 2012; Gurney et al., 2015) . Additionally, PDE expression is assumed to decrease with aging (e.g. Reyes-Irisarri et al., 2007) . Whether this is an age-related decrease or a compensatory mechanism is not known (Richter et al., 2013 )(see Table 2 ).
From a therapeutic perspective, the response of a biological system to an endogenous or exogenous molecule depends upon the dose. Therefore, it is crucial to perform what is termed 'dose-response curves' (often inverted-U shaped). In the current review, these dose-response curves explain optimal levels of performance by cAMP/PKA or cGMP/ PKG activity and bioavailability. Pharmacological agents thus aim to induce optimal levels of cyclic nucleotides thereby enhancing performance (cognition enhancement). Aging and mental illness can increase or decrease levels of cAMP and/or cGMP. This change in cyclic nucleotide activity and bioavailability can be compensated by pharmacological agents returning them to optimal levels. Regarding PDEs and their respective inhibitors, it appears most promising to target PDEs with increased expression. This way, cognition and plasticity deficits resulting from impaired cyclic nucleotide signaling might be improved by inhibiting specific PDE isoforms. However, PDE inhibition might have negative effects on cognition and plasticity when PDEs are already downregulated and cyclic nucleotide levels and protein kinase activity are high which results in a shift of the dose-response curve to the left. In this scenario, elevating cAMP or cGMP levels might go over a physiological level and disrupt signaling. Along this line, high doses of the PDE4 inhibitor rolipram impaired prefrontal cognitive function in aged, but not young monkeys, likely due to overstimulation of the already disinhibited cAMP/PKA signaling pathway in the aged prefrontal cortex (Ramos et al., 2003; Arnsten et al., 2005) .
The review will continue with an overview of the clinical data of PDE inhibitors per PDE family for disorders related to the corticostriatal and hippocampal circuits (see Table 3 ). This includes both cognition enhancing effects as well as effects on motor function and affect. For subclasses of PDEs and their inhibitors that not yet progressed to clinical trials a short preclinical summary is provided.
Clinical overview

Phosphodiesterase 1
PDE1 is a dual substrate enzyme hydrolyzing both cAMP and cGMP (Table 1) . Vinpocetine (Cavinton®, Intelectol®; Richter Gedeon) has been used historically to inhibit PDE1 (Vereczkey, 1985) and has been tested for its cognition enhancing properties for almost 30 years (DeNoble, 1987) . However, vinpocetine should be considered a nonselective PDE1 inhibitor since it has substantial other activities, including inhibition of Na 2+ channels and IκB kinase. Clinical trials with vinpocetine advanced to Phase IV for the treatment of memory impairment. Positive effects on cognition of vinpocetine were observed in a study with healthy females (Subhan and Hindmarch, 1985) . Likewise, positive effects were claimed in a study testing a vinpocetine/Gingko biloba compound in healthy adults (Polich and Gloria, 2001 ). In a similar population, vinpocetine has been tested on cognition as an ingredient in CAF+ (Nootrobox) capsules after a single administration and shown not to affect cognitive performance (Caldenhove et al., 2017) . In elderly, vinpocetine was tested as nutritional supplement Cognitex® (Life Extension) on memory impairments in elderly (ClinicalTrials.gov Identifier: NCT00719953) (Richter et al., 2011) . The outcome of this study was positive as vinpocetine showed a positive effect on memory. However, this study was not a placebo-controlled open label study and Cognitex® is a mixture not only containing vinpocetine and possesses other activities in addition to effects on PDE1 activity. Therefore it can be questioned whether positive effects on memory functioning were in fact due to PDE1 inhibition. Previously, vinpocetine was already proven to be ineffective in treating cognitive impairment in Alzheimer's disease patients (Thal et al., 1989; Szatmari and Whitehouse, 2003) . In summary, vinpocetine improved memory functioning in healthy volunteers, provided a questionable improvement in aged subjects and failed to improve memory functioning in Alzheimer's disease patients. As a result, vinpocetine was never approved by the Food and Drug Administration (FDA) for treatment of memory impairment. Of note, vinpocetine is still widely used as a supplement for vasodilatation and as a nootropic for the attenuation of memory impairments as seen in for instance Mild Cognitive Impairment (MCI) (Valikovics et al., 2012) , organic psychosyndromes (Hindmarch et al., 1991) or elderly with chronic cerebral dysfunction (Balestreri et al., 1987) . Of note, positive effects in elderly with chronic cerebral dysfunction are likely mediated via vasodilatation. Secondly, Intra-Cellular Therapies Inc. has developed the novel PDE1 inhibitor ITI-214, which unlike vinpocetine, has high selectivity for inhibition of PDE1 enzymes . In a series of Phase I single and multiple ascending dose studies performed in the United States (US) and Japan, ITI-214, given orally and once-a-day was shown to be safe and well-tolerated, with a linear pharmacokinetic profile. This study has been reported in a press release (http://www. intracellulartherapies.com/products-technology/pde-inhibitorplatform.html), where the company concludes that "these studies represent a significant milestone as the first demonstration of the safety of a potent and highly specific PDE1 inhibitor in humans" (ClinicalTrials.gov Identifier: NCT01900522; healthy participants and schizophrenia patients). This new compound finally offers an alternative to the non-selective PDE1 inhibitor vinpocetine as ITI-214 has now shown to improve the memory processes of acquisition, consolidation, and retrieval across a broad dose range (0.1-10 mg/kg, p.o.) . Clinical development of ITI-214 is currently in progress.
Recently, 6-(4-Methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4′,3′:4,5]thieno[3,2-e][1,2,4]triazolo [1,5-c]pyrimidin-5(6H)-one (Dart Neuroscience) was identified as an orally bioavailable and brain penetrating PDE1B enzyme inhibitor with potent object recognition memory enhancing effects in rats (Dyck et al., 2017) . Additionally, Pfizer disclosed a brain-penetrating quinazolinebased PDE1 inhibitor PF-04822163 (PDE1B IC 50 : 0.0024 μM), but no efficacy data was disclosed (Humphrey et al., 2014) .
Phosphodiesterase 2
PDE2 is a dual substrate enzyme hydrolyzing both cAMP and cGMP (Table 1) . BAY 60-7550 (BAYER) was the first developed selective PDE2 inhibitor available (Boess et al., 2004) , which to our knowledge was never advanced to clinical trials. Another early compound was ND-7001 (developed by Université de Strasbourg/Neuro3d), which only made it up to Phase I clinical trials to investigate safety, tolerability and pharmacokinetics (for the indication anxiety and depression). The compound was reported to be safe and well tolerated but this research was discontinued in 2010 (Gomez and Breitenbucher, 2013) . Exisulind (Aptosyn®; Cell Pathways, Inc.) is another developed PDE2 inhibitor, which also has PDE5-inhibiting activity. This drug induces apoptosis in a broad range of cancer cell lines and inhibits the formation and growth of cancer in several animal models. Presently, this compound has been tested in Phase III clinical trials for breast, lung, prostate, and colon tumors (ClinicalTrials.gov Identifier: NCT00041054, NCT00078910, NCT00026468, NCT00037609).
Due to renewed interest in PDE2 as a target for cognition enhancement in recent years, several new PDE2 inhibitors have been developed by pharmaceutical companies including Boehringer Ingelheim, Pfizer, Johnson & Johnson, Merck, Altana Pharma and Takeda (for a review see Gomez and Breitenbucher, 2013) . For example, Pfizer's PF-05180999 was tested in two Phase I trials for the treatment of migraine, of which one was terminated prematurely due to safety concerns and the other trial was withdrawn prior to participant enrollment (ClinicalTrials.gov Identifier: NCT01981486 and NCT01981499). Recently, Takeda has initiated a Phase I trial to examine the degree and duration of brain PDE2 enzyme occupancy and target engagement as a function of their PDE2 inhibitor TAK-915 plasma concentration in order to guide dosing and schedule for future clinical studies in schizophrenia with TAK-915. The indication for TAK-915 has been set to cognitive impairment in schizophrenia (Mikami et al., 2017) . Schizophrenia (cognitive symptoms) is the first neuropsychiatric disorder clinically investigated (Table 3) .
Phosphodiesterase 3
PDE3 is a dual substrate enzyme hydrolyzing both cAMP and cGMP (Table 1 ). The PDE3 inhibitor cilostazol (Pletal®; Otsuka Pharmaceutical) is approved by the FDA for the treatment of intermittent claudication and has additionally been investigated as a prevention for stroke recurrence in two Phase IV studies (ClinicalTrials.gov Identifier: NCT00216749, NCT00234065; no results disclosed). With regards to corticostriatal and hippocampal circuitry, cilostazol has been tested in both Alzheimer's disease and schizophrenia trials.
Related to Alzheimer's disease, four clinical trials have been performed with cilostazol. In a first pilot trial of Arai and Takahashi, 2009 , 10 mild to moderate Alzheimer's disease patients received 100 mg cilostazol per day as add-on to donepezil (5 mg/day) for a variable period of time, ranging between 1 and 13 months. This study was an openlabel, uncontrolled trial. In this small group, a statistically significant improvement on the Mini Mental State Examination (MMSE) was reported during the first six months of follow up.
Secondly, Sakurai et al. (2013) investigated the effects of cilostazol on cognition and regional cerebral blood flow (rCBF) in elderly patients with Alzheimer's disease and cerebrovascular disease. The cilostazol group did not show any statistically significant changes in cognitive function test scores, whereas the control group showed statistically I  TBD  TBD  TBD  PDE2  TBD  TBD  TBD  Phase I  TBD  TBD  TBD  PDE3  TBD  TBD  +  +  TBD  TBD  TBD  PDE4  +  +  Phase II  Phase I  +  TBD  Phase I  PDE5  =  TBD  TBD  =/+  TBD  Phase II  TBD  PDE6  PDE7  TBD  TBD  TBD  TBD  TBD  TBD  TBD  PDE8  TBD  TBD  TBD  TBD  TBD  TBD  TBD  PDE9  TBD  TBD  =  Phase II  TBD  TBD  TBD  PDE10  TBD  TBD  TBD  =  TBD  TBD  Phase II  PDE11  TBD  TBD  TBD  TBD  TBD  TBD  TBD + positive effect; = no effect; TBD to be determined; +? Questionable positive results due to drug constraints (PDE1).
P.R.A. Heckman et al. Neuroscience and Biobehavioral Reviews 87 (2018) 233-254 significant cognitive decline on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (Japanese version), Revised Wechsler Memory Scale (logical memory-I) and Trail Making Test-A. Analysis of treatment effect revealed that the cilostazol group showed increased rCBF in the right anterior cingulate lobe compared with baseline, whereas the control group showed decreased rCBF in the left middle temporal gyrus compared with baseline. The latter may, at least in part, be responsible for the positive effects of cilostazol. The ability of cilostazol to increase cerebral blood flow in humans has been confirmed before in different studies in chronically treated patient groups (Mochizuki et al., 2001; Kai et al., 2011) . Remarkably, this effect was not found after acute treatment in healthy volunteers (Birk et al., 2004) , which suggests that longer term treatment is necessary to exert effects on cerebral blood flow.
A third similar study was initiated in 2011 by the Seoul National University Hospital (Lee (personal communication); ClinicalTrials.gov identifier: NCT01409564). In total, 36 mild to moderate Alzheimer's disease patients treated with donepezil were included. Subjects were equally divided over a cilostazol (100 mg BID) group and placebo group and treated for a period of 24 weeks. However, no difference between groups was found for cognitive measures which included the MMSE and the cognitive scale of the cognitive portion of the Alzheimer's Disease Assessment Scale.
In a very recent fourth case-control study, 60 patients with stable Alzheimer's disease and treated with acetylcholinesterase inhibitors (types and doses not disclosed) were equally divided into a placebo group and a group receiving cilostazol (50 mg twice per day) as an addon therapy for at least 12 months (Tai et al., 2017a) . Cilostazol was found to improve the MMSE scores and clinical dementia rating sum of boxes scores in the Alzheimer's disease patients already being treated with acetylcholinesterase inhibitors. Summarizing, it results in two positive findings with a very small sample size, one questionable positive finding due to effects on cerebral blood flow and one study finding no effect.
Two retrospective studies with patients already on cilostazol (e.g. for the prevention of stroke or peripheral artery disease) reported that average daily doses above 100 mg for at least 6 months improved MMSE scores in MCI patients (Taguchi et al., 2013) and mild Alzheimer's disease patients as add-on to 10 mg donepezil per day (Ihara et al., 2014) . The same research group at the National Cerebral and Cardiovascular Center Hospital (Osaka, Japan) has started a new study investigating the effects on MMSE scores of cilostazol 50 mg twice a day for 96 weeks in patients with MCI (ClinicalTrials.gov identifier: NCT02491268). Estimated primary completion date is 2018. Interestingly, a recent retrospective study reported that patients already using cilostazol (50-100 mg daily for at least 3 months) had a decreased risk of incidence of dementia compared to patients not using the drug (Tai et al., 2017b) . Of note, this effect was mainly in cilostazol users with ischemic heart disease and cerebral vascular disease.
Regarding schizophrenia, one open-label pilot study of six patients has been conducted testing the effects of cilostazol on cognition (Shirayama et al., 2011) . Patients were stable on second generation neuroleptics, combined with biperiden and, in most cases, a benzodiazepine. Treatment consisted of two weeks daily 25 mg cilostazol and six weeks daily 50 mg cilostazol. Six cognitive tasks assessing prefrontal functioning and one memory task were performed. Results on the Trial Making Test showed a significant decrease after eight weeks of cilostazol treatment compared to baseline suggesting improved processing speed, visuo-motor search skills and simple attention. However, some of these cognitive functions were included in other tasks as well, in which no significant improvement was found. Of note, the patients were medicated with agents known to have pro-cognitive effects. Therefore, it is possible that the resulting improvement is an interaction effect. On the other hand, PDE inhibitors may be used as add-on therapy by patients in daily life as well.
Of note, possible side effects of the PDE3 inhibitor cilostazol include most commonly headache, diarrhea, abnormal stools, and since it is a quinolinone derivative also irregular heart rate and palpitations (Chapman and Goa, 2003) . Therefore it is dangerous for people with severe heart failure and can only be given to people without this indication. It is also contraindicated in patients with severe hepatic or renal impairment.
Phosphodiesterase 4
PDE4 is cAMP specific (Table 1) . PDE4 inhibitors are being investigated as a treatment for numerous disorders. PDE4 was initially considered as a possible target for the development of drugs for the treatment of depressive disorders (Esposito et al., 2009) . In this respect the PDE4 inhibitor rolipram has been widely investigated. First clinical studies showed a good antidepressant response to rolipram treatment (Zeller et al., 1984; Fleischhacker et al., 1992) . However, rolipram produces severe dose-limiting side effects including: emesis, headache, gastric hyper secretion, nausea and vomiting. This has put a serious hold on the further development of rolipram and other related PDE4 inhibitors. It also prevented rolipram from reaching the market. Yet, a clinical Phase II trial was started in 2006 to reevaluate the antidepressant properties of rolipram (estimated study completion date: December 2013). Again, no details are available to the scientific community. Another PDE4 inhibitor, ND1251, was reported to improve memory in a group of 8 depressed subjects (http://www.outsourcingpharma.com/Preclinical-Research/PDE4-re-emerges-as-depressiontherapy. At the moment, "second generation'' PDE4 inhibitors are being developed, which are supposed to have less-emetic side effects, and are being studied for other disorders besides that of depression.
For (Leaker et al., 2014) ). In 2005, Roche stopped clinical development of MEM 1414 and its back-up candidate, MEM 1917, and Memory Pharmaceuticals regained rights to these agents, intending to move them into Phase II trials. However, Roche acquired the biotech company in a 2008 merger, and it is unclear whether development of MEM 1414, or any of the other PDE4 inhibitors is currently being pursued.
Another therapeutic agent, MK-0952 (Merck; Gallant et al., 2010) , was investigated in a Phase II study in patients with mild to moderate Alzheimer's disease, completed in 2008 but no results disclosed (ClinicalTrials.gov Identifier: NCT00362024). Additionally, HT-0712 (Dart Neuroscience; MacDonald et al., 2007) was tested in several Phase I and Phase II studies on age-associated memory impairment and reported online in 2008 to improve long-term memory (http://www. dartneuroscience.com/press_releases/july_22_2008.pdf).
Subsequently, the PDE4 inhibitor roflumilast (Daxas®, Daliresp®; AstraZeneca, initially Takeda/Nycomed) was approved in 2011 as an antiinflammatory drug for the treatment of Chronic Obstructive Pulmonary Disease (COPD) (Izquierdo and Aparicio, 2010; Puhan, 2011) . Roflumilast was tested by Takeda in a Phase I study to determine whether a scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil in healthy adults (ClinicalTrials.gov Identifier: NCT02051335; no results disclosed). Recently, a Phase II study was completed investigating whether roflumilast improves memory, attention, information processing and executive function in healthy humans (Van Duinen et al., 2017) . It was reported that an acute single dose of 0.1 mg improved immediate recall performance on the 30-word Verbal Learning Task (VLT) and was accompanied by an enhanced P600 peak during the presentation of the words in the third immediate recall trial. Additionally, the same 0.1 mg dose of roflumilast improved sensory gating of the P50 peak at the Fz electrode in that study . Doses of 0.3 and 1 mg were ineffective. Interestingly, the effective low dose is 5 times lower than the approved dose for COPD treatment and, therefore, it is devoid of the side effects typical for PDE4 inhibitors (in particular emesis). Another recent study (ISRCTN registry ID ISRCTN96013814; EudraCT Number 2013-001223-39) of Maastricht University in collaboration with Takeda investigated the effects of roflumilast (single administration 0.1, 0.25, and 1 mg) on cognition in elderly subjects and subjects with age-associated memory impairment (all aged 60-80 years). Results have not been disclosed yet.
Another PDE4 inhibitor recently developed is BPN14770 from Tetra Discovery Partners (Burgin et al. 2010) . BPN14770 is a small molecule, subtype selective, negative allosteric modulator of PDE4D and was evaluated in two Phase I (single and multiple) ascending dose studies (ClinicalTrials.gov Identifier: NCT02648672 and NCT02840279). In addition, cognitive benefit was explored in the elderly subjects (age 60 and older) enrolled in the multiple ascending dose study. In a press release it has been reported that BPN14770 was safe and well-tolerated in both studies. Headaches were the most frequently reported adverse event in the high dose group of the elderly. In addition, a post hoc analysis of the elderly subjects demonstrated significant improvements with an effect size > 0.70 in two measures of working memory at the low and mid doses of 10 and 20 mg, respectively, given twice on a day over a period of two weeks.
In the field of dementia, studies have also been performed in larger groups. Denbufylline is a xanthine derivate with PDE4 inhibitory activity (Miyamoto et al., 1994) . In total, 336 patients with different types of dementia received denbufylline for 16 weeks (Treves and Korczyn, 1999) . Patients were assigned to one of four treatment groups (placebo, 25, 50 or 100 mg BID). Every four weeks patients were tested on a cognitive battery consisting of the MMSE, digit symbol substitution subtests of the Wechsler Adult Intelligence Scale (WAIS), and the vocabulary subtest of the WAIS. Patients receiving denbufylline showed a 3% increase on the MMSE, which was statistically different from the 4% decrease in the placebo group. However, the clinical meaning of the increase needs to be determined. Additionally, Saletu et al. (1992) performed a study in which 96 mildly to moderately demented patients were assigned to a 12 week treatment period of either denbufylline (100 mg BID) or placebo. Patients were assessed on the Clinical Global Impression, the Mini-Mental State (Folstein et al., 1975) , the SCAG (Shader et al., 1974) and the Digit-Symbol Substitution Test (Wechsler, 1956) . Secondary target variables were the Trail-Making Test (Oswald and Fleischmann, 1982) and the Digit Span Test (Wechsler, 1956 ). In addition, electrophysiological correlates were included. In both groups, patients showed treatment-associated improvements on all tasks, with significantly stronger increases in the denbufylline group as compared to the placebo group. Clinical Global Impression was reduced with one point in the denbufylline group, based on which the authors concluded that the denbufylline induced changes were clinically relevant.
Subsequently, PDE4 inhibitors were also tested as a treatment for cognitive impairment related to schizophrenia. In schizophrenia patients, Takeda conducted a Phase I proof of mechanism study to determine whether cognitive impairment associated with schizophrenia is attenuated by add-on roflumilast administration to second generation antipsychotics (ClinicalTrials.gov Identifier: NCT02079844; no results have been disclosed yet). Modulation of PDE4 activity has been implicated in the cognitive and sensorimotor gating deficits seen in schizophrenic patients, although PDE4 expression is decreased in schizophrenic patients in striatum, cortex and thalamus (see Table 2 ). The involvement of PDE4 in schizophrenia is also supported by interaction of PDE4B with Disrupted in schizophrenia 1 (DISC1) (Millar et al., 2005; Clapcote et al., 2007; Murdoch et al., 2007) , which is a genetic susceptibility factor for schizophrenia (Chubb et al., 2008) , and by the association of PDE4B polymorphisms with schizophrenia (Pickard et al., 2007; Fatemi et al., 2008; Numata et al., 2008) . Clinical efficacy of PDE4 inhibitors as therapy for any type of symptoms in schizophrenia remains to be shown.
Finally, PDE4 inhibitors were also tested for their potential as a therapy for Huntington's disease. The new experimental PDE4 inhibitor GSK356278 was tested by GlaxoSmithKline as a new treatment for Huntington's disease in 2 subsequent Phase I studies. In 2012, the first Phase I study was completed investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK356278 (ClinicalTrials.gov Identifier: NCT01573819). GSK356278 was well tolerated when it was given as a single dose to healthy people and in this study the objective was to observe effects of GSK356278 after daily intake. Subsequently, a second Phase I positron emission tomography (PET) brain occupancy study of GSK356278 was conducted in male healthy volunteers (ClinicalTrials.gov Identifier: NCT01602900; no results are disclosed). It is currently unclear whether this PDE4 inhibitor treatment is aimed at the motor or cognitive symptoms observed in Huntington's disease.
Of note, Ibudilast (or AV-411) is another PDE4 inhibitor in development as an anti-inflammatory drug to treat, for instance, Amyotrophic Lateral Sclerosis (ALS) (ClinicalTrials.gov Identifier: NCT02238626). However, this compound not only inhibits PDE4 but also serves as a glial activator. CNS applications of AV-411 are being explored in clinical Phase II studies, i.e., pain and drug abuse (ClinicalTrials.gov Identifier: NCT00723177, NCT01217970, NCT02025998, NCT01860807).
Phosphodiesterase 5
PDE5 is specific for cGMP (Table 1) . Like PDE3 and PDE4 inhibitors, PDE5 inhibitors are well-known for their vascular effects. More specifically, PDE5 inhibition causes relaxation of smooth muscles in blood vessels, hence its importance for the treatment of erectile dysfunction (Zusman et al., 1999) . Sildenafil (Viagra®; Pfizer), vardenafil (Levitra®; BAYER/GSK) and tadalafil (Cialis®; Eli Lilly/ICOS) are examples of FDA approved PDE5 inhibitors for the treatment of erectile dysfunction. Because of its vasodilatory properties, sildenafil and tadalafil are also FDA approved under the names of Revatio® and Adcirca®, respectively, for the treatment of hypertension of the pulmonary artery.
PDE5 inhibitors have been tested as therapy in the cognitive, motor and affective domain. Related to cognition, sildenafil has been tested in clinical trials in the field of Alzheimer's disease. Grass et al. (2001) tested six male healthy volunteers after a single oral dose of 100 mg sildenafil using a test battery of different psychophysical performances tests. Sildenafil enhanced performance in a simple reaction time test, however, no effects were found on short-term memory, divided attention and other psychomotor tasks. A second study by Schultheiss et al. (2001) tested the effects of 100 mg sildenafil in young healthy male volunteers. Sildenafil induced no direct cognition enhancing effects on auditory attention and word recognition. Yet, sildenafil changed certain components of event-related potentials (ERPs). Also, a reduced negativity in the electroencephalogram (EEG) was found during the word recognition experiment after sildenafil treatment. The authors state that the former indicates improved focused attention and the latter an effect on information processing (Schultheiss et al., 2001) .
Two additional studies in healthy volunteers conducted by Reneerkens et al. (2013a; 2013c) investigated the effects of vardenafil on information processing (sensory gating), reaction time responding, executive function and memory performance (e.g. word learning), while EEG activity was recorded. Both 10 and 20 mg vardenafil (for erectile dysfunction recommended doses) induced no prominent effects on information processing, reaction time responding, cognition or EEG measures. This means that all four studies in healthy volunteers found no effect of PDE5 inhibition on memory tasks.
The cognition enhancing potential of PDE5 inhibitors was also investigated in trials related to schizophrenia. Goff et al. (2009) showed that sildenafil treatment when added to antipsychotic treatment did not affect cognition in patients diagnosed with schizophrenia. Another study, investigating the effects of repeated dosing of the PDE5 inhibitor udenafil (Zydena®; Dong-A Pharmaceutical) in patients suffering from erectile dysfunction, demonstrated that this treatment improved performance of these patients on the Korean version of the MMSE, and on an assessment battery measuring frontal executive function (Shim et al., 2011; Shim et al., 2014) . Of note, PDE5 inhibitors have not clinically been tested as antipsychotics in schizophrenia. Effects of PDE5 inhibitors on motor functioning were only investigated up to a Phase II study. Sildenafil was tested for its efficacy in reducing dyskinesias in patients with Parkinson's disease (ClinicalTrials.gov Identifier: NCT02162979). However this study was recently terminated due to insufficient participant inclusion.
Concerning PDE5 inhibition and affect, 40 patients with schizophrenia received chronic treatment of sildenafil (75 mg/day) as augmentation therapy to risperidone (6 mg/day). The principal measure of outcome was Positive and Negative Syndrome Scale (PANSS). The combination of risperidone and sildenafil showed a significant superiority over risperidone alone in decreasing negative symptoms and PANSS total scores over the 8-week trial (cognitive measures were not included in this study) (Akhondzadeh et al., 2011 ).
Phosphodiesterase 6
In contrast to other PDE families, the cGMP specific PDE6 family is restricted to retinal rod and cone cells and the pineal gland (Table 1; Miki et al., 1975; Morin et al., 2001; Ridge et al., 2003; Lakics et al., 2010) . PDE6 is a key component in the visual transduction cascade and is known as the photoreceptor PDE (Cote, 2006) . Therefore, PDE6 inhibitors are currently not under clinical investigation for CNS treatments.
Phosphodiesterase 7
Like PDE4, PDE7 is highly specific for cAMP (Table 1) . Preclinical research into PDE7 inhibitors is currently emerging and therefore PDE7 inhibitors are not under clinical investigation yet (for a review see Jankowska et al., 2017) . So far, preclinical studies have shown procognitive and neuroprotective effects in the cognitive domain (PerezGonzalez et al., 2013; Lipina et al., 2013) . Furthermore, PDE7 inhibitors have also shown neuroprotective effects in motor functioning in multiple sclerosis (Mestre et al., 2015) and Parkinson's disease rat models (Morales-Garcia et al., 2011; Morales-Garcia et al., 2015a,b) as well as Parkinson's disease mice models MoralesGarcia et al., 2015a,b) . Recent preclinical data demonstrate a dopamine D1 receptor-mediated transcriptional activation of PDE7B through the cAMP/PKA/CREB pathway in striatal neurons (Sasaki et al., 2004) . Activation of this D1 receptor cascade could explain the pro-cognitive (frontal cortex) and neuroprotective (striatum) effects of PDE7 inhibitors observed in the first preclinical studies.
Phosphodiesterase 8
Like PDE4 and PDE7, PDE8 is highly specific for cAMP (Table 1) . Preclinical studies with PDE8 inhibitors (e.g. PF-04957325 ), which do not differentiate between different PDE8 isoforms, are just starting to emerge. Therefore, PDE8 inhibitors are currently not under clinical investigation for CNS treatments yet. Interest in PDE8 relates to the regulatory role of this PDE in steroidogenesis Shimizu-Albergine et al., 2012; , in addition to PDE2, PDE4 and PDE5 . However, PDE8B knockout mice demonstrated increased contextual fear conditioning performance, increased spatial memory performance, increased performance in an appetitive instrumental conditioning task, increased motor-coordination, and an attenuation of age-induced motor coordination decline . In addition, basal anxiety levels increased as indicated by the elevated-plus maze and open field task. These findings indicate that selective antagonism of PDE8B may be an attractive therapeutic target for the cognitive and motor domains.
Phosphodiesterase 9
PDE9 has the highest affinity for cGMP (Table 1) . So far, research into the applicability of PDE9 inhibitors in CNS disorders is still scarce. Preclinical studies have shown promising results regarding cognition enhancement related to Alzheimer's disease, schizophrenia and Huntington's disease (van der Staay et al., 2008; Hutson et al., 2011; Vardigan et al., 2011; Kleiman et al., 2012; Kroker et al., 2014; Nagy et al., 2015) . In contrast to PDE8 inhibitors, antagonists of PDE9 have entered clinical trials. In 2009 the Pfizer PDE9 inhibitor PF-04447943 entered a Phase II study comparing PF-04447943 to placebo in subjects with mild to moderate Alzheimer's disease to evaluate the effects of PF-04447943 on cognitive symptoms related to Alzheimer's disease (Schwam et al., 2014) . Recently, data from that study have been disclosed and 25 mg (BID) during twelve weeks had no effect on cognition in patients with mild to moderate Alzheimer's disease. It was suggested that the treatment duration may not have been long enough and/or, due to extensive neurodegeneration in Alzheimer's disease, prodromal Alzheimer's disease patients or age-associated cognitive impaired subjects may be a better target population for future studies. Boehringer Ingelheim is currently investigating their PDE9 inhibitor BI 409306 as a cognition enhancer in Phase II clinical trials for both Alzheimer's disease and schizophrenia (ClinicalTrials.gov Identifier: NCT02337907 and NCT02281773; Wunderlich et al., 2016) after positively completing their Phase I trials (Moschetti et al., 2016; Boland et al., 2017) . The Phase I schizophrenia trial of BI 409306, showed no improvement of cognitive functioning and no improvement in PANNS score in schizophrenia patients (Brown et al., 2017) . However, these were only secondary outcomes during a Phase I trial and the true potential of this inhibitor will have to be shown in future Phase II studies. In the meantime the search for other selective PDE9 inhibitors continues (Su et al. 2016; Hassaan et al. 2016 ) and future clinical trials will have to show the full potential of PDE9 inhibitors in disorders related to dysfunctional hippocampal and corticostriatal circuits.
Phosphodiesterase 10
PDE10 is a dual-substrate enzyme hydrolyzing both cAMP and cGMP (Table 1) . The most widely used PDE10 inhibitor is papaverine, though more selective PDE10 inhibitors have been developed, including MP-10, PQ-10, TAK-063, THPP-1 and TP-10. PDE10 inhibitors have mainly been investigated for their antipsychotic potential. Initial preclinical antipsychotic efficacy of PDE10 inhibitors was promising, though subsequent clinical trials showed unexpected extrapyramidal side effects, hampering PDE10 inhibitors in reaching the market as antipsychotic treatment. An example of the latter is provided by the failure of the Phase II clinical trial of Pfizer in which their PDE10 inhibitor MP-10 (or PF-02545920) showed no efficacy and produced unexpected motor side effects (akathisia and dystonia; DeMartinis et al., 2012) . These findings are in line with data from primates (Uthayathas et al. 2014 ) and non-human primates (Bleickardt et al. 2014) . Despite serious challenges, the pharmaceutical industry remains interested in PDE10 inhibitors for their antipsychotic potential. As a result, Takeda is currently recruiting participants for a clinical Phase II efficacy and safety study for TAK-063 in participants with acute exacerbation of schizophrenia (ClinicalTrials.gov Identifier: NCT02477020). Additionally, a Phase I study by Hoffmann-La Roche has just been completed in which the safety, tolerability and pharmacokinetics of RO5545965 in patients with schizophrenia on risperidone was tested (no results have been posted; ClinicalTrials.gov Identifier: NCT02019329). Of note, in 2012 Amgen started and terminated a Phase I study to assess the safety and tolerability of their PDE10 inhibitor AMG 579 following a single oral dose administration in healthy subjects (Part A) and in patients with schizophrenia or stable schizoaffective disorder (Part B) (ClinicalTrials.gov Identifier: NCT01568203). Other clinical trials have been discontinued including trials by Janssen, Lundbeck, Astellas, Forum, Sunovion and University of Copenhagen, while Roche and Mochida are still conducting Phase I trials (Geerts et al., 2017) Pharmaceutical companies have also started to repurpose their PDE10 inhibitors to therapies for Huntington's disease. Pfizer's MP-10 was tested for safety and efficacy in Huntington's disease patients (ClinicalTrials.gov Identifier: NCT02197130) after exhibiting promising preclinical outcome (Beaumont et al., 2016) . The Phase II trial failed to find the efficacy for which it hoped. In December 2017, Pfizer announced that the therapeutic intervention in its much-anticipated Amaryllis trial produced negative results. The drug failed to show significant improvement in movement, cognition, or behavior. As a result, Pfizer has terminated the open-label 12-month extension study. The trial included 271 individuals with HD in five countries. Likewise, a Phase II clinical trial was conducted by Omeros in which Huntington's disease patients were treated with OMS824 after the compound had previously been tested in a Phase II trial in schizophrenia patients (no results disclosed; ClinicalTrials.gov Identifier: NCT01952132). The Omeros Huntington's disease trial was a sequential-cohort dose-escalation study that evaluated the safety and tolerability of OMS824 over four weeks (ClinicalTrials.gov Identifier: NCT02074410). In parallel with the clinical OMS824 trial, Omeros was conducting preclinical rat studies to support clinical trials of longer duration. However, based on data produced by these preclinical studies, there might be a safety issue and based on follow-up communications with the FDA, Omeros has suspended the ongoing Huntington's disease trial. The FDA has requested that Omeros further evaluates the preclinical data in order to characterize the compound more fully prior to reinitiating the clinical trial (http://investor.omeros.com/ phoenix.zhtml?c=219263&p=irol-newsArticle_Print&ID=1979683). Additional support for the therapeutic potential of PDE10 inhibitors in Huntington's disease comes from a recent study which shows that PDE10 levels are lowered early before symptom onset in Huntington's disease (Niccolini et al., 2015b) . However, in the introduction section, we have argued that it seems most promising to target PDEs with increased expression. Whether this is cause or consequence remains therefore to be determined. Possibly, it resembles a consequence of the degeneration of striatopallidal MSNs and the PDE10 enzymes within and in that case PDE10 inhibitors could contribute as therapy. On the other hand, if the decreased expression is causal to the development of symptoms, PDE10 inhibition will only contribute to the progression of the disease. A recent Phase 0 study measured the availability of the PDE10A enzyme in Huntington's disease gene expansion carriers (HDGECs) using the recently developed radioligand [18F]MNI-659 (ClinicalTrials.gov Identifier: NCT02061722) (Russell et al., 2016) . The cross-sectional study, supports [(18)F]MNI-659 PET imaging of PDE10 as a useful biomarker to track Huntington's disease progression. Similar studies are or have been conducted by other pharmaceutical companies (Geerts et al., 2017) .
Of note, Niccolini et al. (2015a) demonstrated striatal and pallidal loss of PDE10 expression in Parkinson's disease patients, associated with duration and severity of motor symptoms and complications. This would imply a link between dopaminergic nigrostriatal degeneration and the expression of PDE10 in striatum and pallidum. While the observed decline in Huntington's disease might be a direct consequence of both D1 receptor and D2 receptor MSN dysfunction, the decrease in PDE10 in Parkinson's disease might be attributed to a compensatory mechanism to possibly modulate D1R-mediated signaling and restore the equilibrium between direct and indirect pathways (see Geerts et al. (2017) for a more exhaustive discussion). In hyperkinetic movement disorders like Huntington's disease, PDE10 may thus be a promising target for pharmacological agents (PDE10 inhibitors enhance the little cAMP signaling that is left in the indirect pathway).
Phosphodiesterase 11
PDE11 is a dual-substrate enzyme hydrolyzing both cAMP and cGMP (Table 1) . PDE11 is the most recently identified member of the PDE superfamily. Especially in the brain, little is understood of its exact function. Interestingly, PDE11A knockout mice showed subtle psychiatric-disease-related deficits, including hyperactivity in an open field, increased sensitivity to the glutamate NMDA receptor antagonist MK-801, as well as deficits in social behaviors (social odor recognition memory and social avoidance) (Kelly et al., 2010) . Subsequent preclinical studies have confirmed and specified the role of PDE11 in social memories, i.e. PDE11 knockout mice exhibit normal short-term memory for social odor recognition and social transmission of food preference, but showed impaired long-term memory 24 h post training. Importantly, PDE11A knockout mice showed normal long-term memory for nonsocial odor recognition (Hegde et al. 2016a; Hegde et al. 2016b ). Therefore, PDE11 seems to fulfill a special role in the consolidation of social memories. In addition, PDE11A knockout mice showed enlarged lateral ventricles and increased activity in CA1 (as per increased Arc messenger RNA (mRNA)), phenotypes associated with psychiatric disease. Currently, the first PDE11 inhibitors have been developed (Ceyhan et al., 2012) , though, to the best of our knowledge, no clinical studies are or have been conducted yet.
Discussion
The corticostriatal and hippocampal circuits constitute the neurobiological basis for several prominent neuropsychiatric disorders, including Parkinson's disease, Huntington's disease, ADHD, autism spectrum disorder, schizophrenia, obsessive-compulsive disorder, bipolar disorder, anxiety disorders, Alzheimer's disease and depression. The cyclic nucleotides cAMP and cGMP are intracellular signaling molecules that regulate a myriad of cellular processes within these circuits. In the current manuscript, we mainly focused on the role of cAMP, cGMP and their phosphodiesterases in intra-cellular signaling processes related to neuroplasticity by describing how different PDE inhibitors with different substrate specificity affect the cognitive, motor and affective domain in clinical trials.
Corticostriatal circuits
cAMP plays a major role in corticostriatal functioning due to its abundant expression in cortical and striatal neurons, positioning them in an ideal location to exert maximal effect on basal ganglia direct, indirect and hyperdirect pathways and, therewith, on behavioral domains controlled by the corticostriatal circuit (Fig. 2) . For instance, cAMP is positively coupled to dopamine D1 receptors and co-localized with PDE1B in the frontal cortex (Nishi et al., 2011; Wennogle et al., 2017) . As a result PDE1 inhibitors are investigated in clinical trials for their cognition enhancing potential in schizophrenic patients, as these patients are characterized (among others) by frontal dopaminergic hypofunction (Meyer-Lindenberg et al., 2002; Van Os and Kapur, 2009) . Within the corticostriatal circuits, cAMP is also involved in the presynaptic release of the neurotransmitters glutamate and dopamine (Schoffelmeer et al., 1985; Imanishi et al., 1997; Rodriguez-Moreno and Sihra, 2013) . By increasing their release, PDE inhibitors affecting presynaptic cAMP pools are hypothesized to benefit disorders characterized by corticostriatal hypodopaminergia like ADHD and Parkinson's disease (e.g. Okimura et al., 2015; Pliszka, 2005; Sagvolden et al., 2005; Arnsten and Pliszka, 2011) . However, no clinical studies have been conducted in this respect yet.
Additionally, cAMP activates postsynaptic CREB-and DARPP-32-mediated intracellular signaling cascades involved in synaptic plasticity of striatal MSNs. This applies to both the direct striatonigral as well as the indirect striatopallidal projections. Based on overall expression patterns in both pathways, PDE1B, PDE2A, PDE4, PDE7B, PDE9A and PDE10A seem to be interesting targets (Lakics et al., 2010) , although most attention and resources have thus far been devoted to the potential of PDE4 and PDE10A due to their role in the dopaminergic modulation of corticostriatal transmission. The main site of action and expression of PDE4 and PDE10A as discussed in this clinical review is inferred from biochemical analyses of striatal cAMP/PKA effectors, behavioral phenotypes of knockout mice and the observation of effects of subtype-specific PDE inhibitors on dopamine-related behavior. The different PDE subtypes are related to different disorders due to their differential expression in one or more of the striatal pathways and, as such, the inhibition of D2 receptor signaling or the stimulation of D1 receptor signaling mediated by striatal cAMP .
For instance, PDE4 inhibitors are being clinically investigated as a treatment for Huntington's disease due to the preferential expression of PDE4 in the indirect compared to the direct pathway. No results have been disclosed yet. It is hypothesized that activation of the inhibitory indirect pathway will symptomatically benefit hyperkinetic movement disorders like Huntington's disease by countering chorea through inhibition of motor output. In a similar way, it is thought to treat dyskinesias including LIDs. Like inhibitors of PDE4, PDE10 inhibitors have made it to clinical trials as a treatment for Huntington's disease due to their expression, and regulation of cAMP levels, in MSNs belonging to the striatopallidal pathway, which is believed to result in activation of this inhibitory pathway (Beaumont et al., 2016) . Because of the restricted localization of PDE10, the philosophy behind it was that the probability of metabolic side effects is highly reduced (Geerts et al., 2017) . Pfizer has recently disclosed that their PDE10 inhibitor MP-10 failed to improve movement or cognition in the company's Huntington's disease Phase II trial. Additionally, PDE10 inhibitors have been investigated in clinical trials for their antipsychotic potential. On the one hand, due to their supposed activation of striatopallidal projections, thereby mimicking the antipsychotic class of D2 antagonists (Nishi et al., 2011) . Unlike PDE4, which mainly regulates adenosine A 2A receptor-activated cAMP/PKA signaling in striatopallidal neurons, PDE10A regulates both dopamine D2 receptor-inhibited cAMP/PKA signaling and adenosine A 2A receptor-activated cAMP/PKA signaling in these neurons and is therefore considered to be the more preferred treatment when compared to PDE4 inhibitors (Nishi et al., 2008; Nishi and Snyder, 2010) . On the other hand, PDE10 inhibitors potentiate dopamine D1 receptor signaling in striatonigral neurons, believed to be responsible for improvement of cognitive function. PDE10 inhibitors have no effect on dopamine synthesis and metabolism at dopaminergic terminals (Nishi et al., 2008) . The schizophrenia hypothesis of PDE10 inhibitors has been extensively confirmed in preclinical studies, though clinical studies are lacking efficacy and extrapyramidal side effects were observed as a result of PDE10 inhibition. Due to the higher expression of PDE10 in the indirect pathway PDE10 inhibitors are not only hypothesized to be effective in treating positive symptoms in schizophrenia, but also in treating obsessive-compulsive disorder and Tourette's syndrome. These hypotheses are, however, merely based on expression patterns instead of cyclic nucleotide dysfunction in these disorders.
Even though cGMP has a more facilitating role in striatal neuroplasticity, PDE10 inhibitors are also believed to hold therapeutic potential for the treatment of schizophrenia and Huntington's disease by elevating striatal cGMP levels. Thereby, increasing neuronal excitability and facilitating glutamatergic corticostriatal transmission. This way, PDE10 inhibitors take full advantage of their dual substrate specificity. Of note, a reduction in motor side effects as a result of PDE10 inhibition after titrating treatment into smaller doses over multiple days is likely due to the effect of cGMP on LTD (Picconi et al., 2011) . Furthermore, many other classes of PDE inhibitors have been described to be tested in clinical trials of schizophrenia. However, these were all related to the treatment of cognitive symptoms, not for their antipsychotic potential. It should also be noted that, in contrast to PDE1 inhibitors, the other classes of inhibitors do not target the frontal dopamine D1 system and are therefore not discussed in the current section.
Due to their relatively high expression in human striatum, the PDE2 family could also be considered an interesting target for disorders related to corticostriatal dysfunction in a similar fashion to PDE10, i.e. by increasing both cAMP and cGMP levels in striatal MSNs (Lakics et al., 2010) . However its widespread distribution is also its major pitfall as it will affect many off-target areas inducing unwanted side effects Polito et al., 2013) . Additionally, the issue with some current PDE2 inhibitors, like BAY 60-7550, is low bloodbrain barrier (BBB) permeability (Reneerkens et al., 2013b) .
In summary, based on the negative outcome of Pfizer's clinical trials for schizophrenia and Huntington's disease, the future for PDE10 inhibitors (or PDE inhibitors in general) for the treatment of corticostriatal disorders is highly uncertain (Geerts et al., 2017) . After very promising preclinical data, the probability that PDE10 will be pursued further in CNS disorders is minimal. A negative outcome of any future trial will jeopardize in all likelihood, further research on inhibitors of other PDE families in neuropsychiatric disorders of the corticostriatal circuits.
Hippocampal circuits
In contrast to corticostriatal circuits, both cAMP and cGMP play a prominent role in hippocampal circuitry. Activation of both second messengers can result in an increase in presynaptic neurotransmitter release, i.e. glutamate and acetylcholine (Colquhoun and Patrick, 1997; Imanishi et al., 1997; Rodriguez-Moreno and Sihra, 2013; Arancio et al., 1995; Colquhoun and Patrick, 1997) . However, for disorders related to the hippocampal circuitry, PDE inhibitors ultimately aim to induce longer-lasting forms of plasticity (Heckman et al., 2015b) . However, most acute (single administration) studies are unlikely to induce neuroplasticity beyond increased neurotransmitter release. This already emphasizes the need for studies with (sub)chronic treatment regimens, resembling a more realistic regimen of patients. The NO/ cGMP pathway as well as the cAMP/PKA pathway, which can both be influenced by specific PDE families and their inhibitors and have already been discussed to play an important role in memory processes, are known to be altered in aged brains (Blokland et al., 2006; DomekŁopacińska and Strosznajder, 2010; Francis et al., 2011) . Therefore, cGMP as well as cAMP are suggested to be linked to Alzheimer's disease (Chen et al., 2007; Jancic et al., 2009) . The eventual downstream activation of CREB provides an interesting opportunity to improve cognitive dysfunction and decreased synaptic plasticity in disorders characterized by cognitive impairment (Lu and Hawkins, 2002; Saura and Valero, 2011) . Recently, it has been suggested that effects of cGMP are in fact mediated via cAMP (Bollen et al., 2014) . Since several PDE subtypes are expressed in the human hippocampus (Lakics et al., 2010) , clinical trials with a plurality of PDE inhibitors have been conducted.
Targeting cAMP, PDE4 inhibitors are most elaborately investigated . High expression of PDE4 in the hippocampus, increased hippocampal levels of cAMP after PDE4 inhibitor treatment, and positive results of PDE4 inhibitors in preclinical trials have resulted in the initiation of clinical trials with PDE4 inhibitors for the treatment of cognitive deficits in Alzheimer's disease. The rationale for testing PDE4 inhibitors in patients with Alzheimer's disease is supported by an increase in expression of PDE4D isoforms 3, 5, 6, 7 and 8 in hippocampi of patients (see Table 2 ). PDE4 inhibitors have been tested in several populations. In healthy young subjects, a single administration of a low dose of the PDE4 inhibitor roflumilast improved cognition in healthy adults (Van Duinen et al., 2017) . The effective dose was substantially lower than the approved dose for the treatment of acute exacerbations in COPD, which had no effect on cognition. Thus, there is a therapeutic window between positive cognitive effects at low dosing and possible emetic effects at high dosing. Although roflumilast is considered a nonselective inhibitor for all PDE4 isoforms (Hatzelmann et al., 2010) , it might be suggested that it has differences in intrinsic properties still, in particular the PDE4B and PDE4D isoforms in the hippocampus. This could also be concluded from previous preclinical work comparing procognitive and emetic-like effects in mice between roflumilast and the similarly non-selective PDE4 inhibitor rolipram (Vanmierlo et al., 2016) . Rolipram induced emetic-like effects at pro-cognitive doses, while roflumilast had a significant difference between the high doses inducing emesis-like behavior and low doses improving cognition. Recently, a single administration of roflumilast has been tested in healthy elderly (ISRCTN registry ID ISRCTN96013814 ). It would be interesting to see if the same therapeutic window can be observed as in healthy adults, yet no data has been disclosed yet. The PDE4 inhibitor BPN14770 has been tested in healthy elderly using a repeated treatment. Also this compound showed a positive effect on cognition. Of note, though BPN14770 is a selective inhibitor for the gene product PDE4D, it does not completely inhibit the enzyme. Actually, it was especially designed for this purpose with the aim to reduce emetic sideeffects (Burgin et al., 2010) . Indeed, the compound was reported to be safe and well tolerated. Besides having being evaluated in healthy elderly, a single administration of roflumilast has been tested in parallel in elderly with age-associated memory impairments (ISRCTN registry ID ISRCTN96013814). Also the data of this study has not been disclosed yet. The PDE4 inhibitor HT-0712 (Dart Neuroscience) has been tested using a repeated administration in two studies with age-associated memory impaired elderly. The first study with HT-0712 reported a positive effect on cognition. The results of the second study with HT-0712 have not been disclosed yet (ClinicalTrials.gov Identifier: NCT02013310). Unfortunately, Dart Neuroscience has recently closed all its operations so the future development of HT-0712 is uncertain.
As stated above, attempts have been made to specifically target PDE4D in Alzheimer's disease. One approach is the development of negative allosteric inhibitors of PDE4D, which do not fully inhibit the enzyme (Burgin et al., 2010) . Another approach is to develop a full PDE4D inhibitor (Maastricht University/Columbia University/University of Genoa) with probably less affinity for the PDE4D isoforms involved in emesis (Bruno et al., 2011) . As such, the first compound Gebr-7b was effective in improving cognition in a mouse APP/PS1 model of Alzheimer's disease (Sierksma et al., 2014) , as was also found for the follow-up compound Gebr-32a in Tg2576 mice (Ricciarelli et al., 2017) . Gebr-7b had no effect on hippocampal Aβ load (Sierksma et al., 2014) . The latter was also reported in previous studies with the classic PDE4 inhibitor rolipram, yet it rescued decreased CREB activation (Gong et al., 2004; Comery et al., 2005) . Thus, activation of the pCREB pathway is likely to make to the synapses and neurons more resistant to the damaging effects of Aβ, i.e. protection by PDE4 works independently of Aβ. Linked to this, it is important to mention that it has very recently been shown that rolipram promoted clearance of aggregated tau in the frontal cortex and hippocampus, and improved cognition in a mouse rTg4510 model of tauopathy (Myeku et al., 2016) . This might possibly be mediated via increased ATP-dependent proteasome phosphorylation/activation and a linked drop in ubiquitin conjugate levels. These are processes described to be dysfunctional in Alzheimer's disease. Thus, it would be interesting to also investigate whether PDE4 inhibition could prevent neurodegeneration in Alzheimer's disease by reducing levels of aggregated tau.
Cyclic GMP has also been a major target in Alzheimer clinical trials. In this respect PDE5 and PDE9 inhibitors have been investigated. Four clinical trials have tested the effects of PDE5 inhibition on memory in healthy volunteers and none of these studies proved a therapeutic benefit on cognitive function. Ceiling effects may be a limiting factor in these studies. Future studies with healthy subjects should therefore test either low-cognitive performers or use deficit models to assess cognition enhancing effects of PDE5 inhibitors. Alternatively, future studies could be aimed at elderly participants or patients. However, mRNA levels of PDE5 may be so low in the brain of Alzheimer's disease patients, that enzyme availability may become an issue during treatment since levels of PDE5 are already low in healthy participants. A ceiling effect might also cause a single dose of PDE5 inhibitor not to be effective and it would therefore be interesting to proceed to (sub)chronic PDE5 inhibitor treatment. Nevertheless, new PDE5 inhibitors for the treatment of Alzheimer's disease are still being identified (Fiorito et al., 2017) . PDE9 inhibitors have more recently been developed. In one Phase II study PF-04447943 showed no effects on cognition in patients with mild to moderate Alzheimer's disease (Schwam et al., 2014) . Boehringer-Ingelheim is currently testing their PDE9 inhibitor BI 409306 in Alzheimer's disease. In December 2014 and January 2015, respectively, two three-month, multinational Phase II trials of BI 409306 began in patients with prodromal AD. One study will compare four doses of BI 409306 to placebo in 288 people with mild to moderate Alzheimer's who have not taken a cholinesterase inhibitor or memantine in the past three months; the other will compare the same doses as add-on therapy in 336 patients who also take donepezil. So far, cGMP has not clinically proven to be an effective target in the treatment of cognitive deficits in Alzheimer's disease. However, based on results of preclinical and Phase I clinical studies, expectations for the Boehringer trial are high.
Of note, the growing field of studies regarding the cognitive enhancing action of PDE4 inhibitors and PDE5 inhibitors raises a discussion regarding the mechanism of action of the above inhibitors. PDE4 and PDE5 inhibitors increase cAMP and cGMP, respectively, which are also known to cause a subsequent vasodilation and increase in glucose metabolism (Paterno et al., 1996) . Therefore, the cognitive enhancing effect of the inhibitors could be due to increased cerebral blood flow and glucose delivery to the brain. However, it has been preclinically shown for both PDE4 and PDE5 inhibitors that their effective dose for improving cognition is below the required dose for inducing vascular and metabolic effects. For example, 1 mg/kg of rolipram (i.p.) rapidly decreased blood flow and glucose metabolism in the brain by 20% and 40%, respectively, and the decrease in glucose metabolism at 30 min post-administration was further decreased by 60% (Ishikawa et al., 2002) . Of note, 1 mg/kg is higher than the effective dose of rolipram to improve memory that lies between 0.01 and 0.03 mg/kg (i.p.). Similarly, sildenafil could increase the mean arterial blood pressure in rats up to 6 h after 10 mg/kg oral administration (Rehse et al., 1999 ). Yet, the effective dose of sildenafil to improve memory is at 1-3 mg/kg after oral treatment. Also, sildenafil had no effect in humans on blood flow in the middle cerebral artery, just as there were no changes in radial and temporal artery diameters (Arnavaz et al., 2003; Kruuse et al., 2003; Kruuse et al., 2009 ). Additionally, a study from Rutten et al. (Rutten et al., 2009 ) actually showed that the cognitive enhancing properties of rolipram and vardenafil in object and spatial memory were not related to any main effects on blood flow and glucose utilization in the rat brain. Finally, there are studies showing that the positive effects of sildenafil (Puzzo et al., 2009; Zhang et al., 2013) and rolipram (MacKenzie and Houslay, 2000; Monti et al., 2006) on cognition are related to activation of pathways that lead to increases in CREB phosphorylation. Altogether the above observations indicate that cognitive enhancing effects of PDE4 and PDE5 inhibitors are attributed to underlying mechanisms related to plasticity rather than cerebrovascular effects.
Dual substrate PDE inhibitors have also been tested in clinical trials for Alzheimer's disease. Targeting both cAMP and cGMP is hypothesized to be especially beneficial due to their function in both early and late consolidation (e.g., Impey et al., 1996; Lu et al., 1999) . For PDE1, five clinical trials with the PDE1 inhibitor vinpocetine were conducted showing mixed results for Alzheimer's disease. Vinpocetine failed to improve memory in Alzheimer's disease patients (Thal et al., 1989; Szatmari and Whitehouse, 2003) and healthy young volunteers (Caldenhove et al., 2017) , though improved memory functioning in healthy female volunteers (Subhan and Hindmarch, 1985) , while questionable results were obtained in 2 studies with healthy adults and elderly (Richter et al., 2011; Polich and Gloria, 2001) (Table 3 ). The validity of the latter result can be questioned since Cognitex is composed of several other ingredients besides vinpocetine. Also, the Gingko biloba mix contained other ingredients. On top of that, vinpocetine itself is already considered a non-selective PDE1 inhibitor as it also inhibits PDE5 and PDE7, in addition to other targets including both Na + and K + channels that control Ca 2+ influx and neuronal excitability.
With the appearance of ITI-214, clinical trials can now be initiated more selectively investigating the clinical potential of PDE1 inhibitors. PDE3 isoforms are generally very low expressed in the human body except for the heart, hence the widespread investigation in cardiovascular trials and the approval of the PDE3 inhibitor cilostazol for the treatment of intermittent claudication by the FDA. Nevertheless, cilostazol's therapeutic potential for the treatment of Alzheimer's disease is widely investigated. One study in Alzheimer's disease patients showed no effects and two showed a positive effect of cilostazol (Arai and Takahashi, 2009; Sakurai et al., 2013) . However, one result has been related to increased cerebral blood flow and should therefore be considered a cerebrovascular effect. Two retrospective studies showed that dementia patients already on cilostazol for cardiovascular diseases exhibited an improvement in cognitive function as assessed by the MMSE. A third retrospective study showed a decreased risk of dementia of patients already on cilostazol. If there is any future for PDE3 inhibitors in CNS disorders it seems most likely to be through its effects on the brain vasculature instead of intracellular cascades related to neuroplasticity or neuroprotection. Although, a recent preclinical study claims that their positive effects of cilostazol on memory function are mediated through intracellular signaling pathways known to be involved in neuroplastic processes related to cognitive decline of the aging human brain with a prominent role for cyclic nucleotides (Yanai et al., 2018) . Anyway, whether via cerebrovascular improvement or increased neuroplasticity, cilostazol seems to hold great promise for the symptomatic treatment of Alzheimer's disease and other dementias.
The cyclic nucleotide-induced phosphorylation of CREB can also result in downstream activation of neuroprotective mechanisms (e.g., via BDNF). The latter can be extended all the way up to proliferation and survival of new neurons (neurogenesis). All other studies into the cognition enhancing potential of PDE inhibitors are mediated via this cascade irrespective of their substrate specificity. Only the PDE1 family has been targeted for its modulation of the dopamine D1 receptor in frontal cortex to improve cognitive function as discussed in previous section of corticostriatal circuits. Inhibitors of PDE2, PDE3, PDE4, PDE5 and PDE9 tested in clinical trials for the treatment of cognitive symptoms in schizophrenia, PDE2 and PDE4 inhibitors for the treatment of cognitive deficits observed in depression, as well as PDE5 inhibitors for the treatment of cognitive symptoms in Parkinson's disease, aim to increase hippocampal neuroprotection via CREB-mediated mechanisms.
To summarize, the results -if reported at all -of the first clinical studies in hippocampal circuits with a PDE3, 4 or 9 inhibitor do not allow drawing any concrete conclusion yet. This might be due to inappropriate dosing and/or choice of the inappropriate patient population. Optimum dosing is extremely important as it will help to reduce unwanted side effects (e.g. emesis, cerebro-and/or cardiovascular effects). Currently, studies with a PDE3 (cilostazol) or PDE9 inhibitor (BI 409, 306) are still ongoing in patients with MCI or Alzheimer's disease, respectively. PDE4 inhibitors (HT-0712, roflumilast and BPN14770) are also being tested in healthy elderly and elderly with age-associated memory impairments. First results have been presented and appear promising and suggest that indeed the optimum dose and/or inhibiting the appropriate PDE isoform hold great promise when tested in the right population of patients with MCI or Alzheimer's disease eventually.
Translational considerations
The main argument for testing an inhibitor of a specific PDE subtype in a particular corticostriatal or hippocampal disorder is protein or mRNA expression in brain areas related to the disorder. Especially, changes in PDE or cyclic nucleotide expression are indicators for the therapeutic potential of an inhibitor. To this end, an extensive review has recently been published in which alterations in cyclic nucleotide signaling associated with aging, dementia, MCI, Alzheimer's disease, Parkinson's disease and Huntington's disease are described (Kelly, 2018) . Therefore, in the current review, we only provide a table (Table 2) with the most important changes in PDE expression levels for the different disorders discussed. However, expression of a PDE subtype in a brain area does not make it an interesting target per se. The different PDE isoforms contain a multiplicity of structural and biochemical properties and are located in specific subcellular compartments, with specific transcriptional and posttranscriptional regulation targeting designated pools of cyclic nucleotides (Keravis and Lugnier, 2012) . The local net amount of cAMP and/or cGMP will eventually determine the cellular and functional fate and as such contribute to the reduction of the pathology or influence the overall signaling in a therapeutic direction.
The wealth of preclinical findings has clearly not yet been translated into clinical efficacy. To bridge the gap between preclinical and clinical findings several translational issues are of importance and should be taken into account. First of all, there is still a great need for a deeper understanding of the fundamental physiology of the corticostriatal and hippocampal circuits including related pathology. For example, future studies need to determine the exact mechanism by which circuitry activation produces normal and pathological behavior and identify the altered PDE isozymes and signalosomes related to the given pathology. Next, the complex interaction and cross-talk between the direct and indirect pathway (Calabresi et al., 2014) as well as the involvement of the hyperdirect pathway is not very clear yet (Mathai and Smith, 2011) . Also, the exact modulatory function of dopamine and acetylcholine in the corticostriatal and hippocampal circuits, respectively, needs to be further elucidated (e.g. Calabresi et al., 2014; Keeler et al., 2014) as should the place for PDEs and cyclic nucleotides herein. In addition, there might be differences in functioning of motor, associative and limbic circuits in particular within the corticostriatal circuits or between hippocampal and corticostriatal circuits in general.
In addition to the need for more basic research into functioning of the corticostriatal and hippocampal circuits in health and disease, more information regarding expression patterns and subcellular localization of PDEs is required. In order to get a better understanding of the localization of the different PDEs selective antibodies or radioactive probes are needed (e.g. Coskran et al., 2006) . Only when the localization of the PDEs in different brain regions and neurons is characterized a better insight can be obtained into how PDE inhibitors modulate these neuronal networks. Further, individual PDEs are recruited in an isoform-specific manner into specialized signalosomes within discrete functional compartments, where they can tightly regulate local cyclic nucleotide concentrations and gradients (Maurice et al. 2014; Keravis and Lugnier 2012) . Therefore, detailed knowledge of splice variantspecific expression patterns and the function of the many signalosomes in which the isoforms are involved is desired. Next, the contribution of dysfunctional signalosomes to the diverse range of symptoms observed in neuropsychiatric diseases should be further unraveled. Increased understanding of the signalosomes in which PDEs are involved and their specific dysfunction in the corticostriatal and hippocampal circuits will aid in making better treatments aimed at underlying causality of disorders instead of merely symptomatic treatment. More detailed knowledge of subcellular localization and changes in cyclic nucleotide functioning will also stimulate the production of more specific (i.e. isoform or splice variant-specific) PDE inhibitors. Increased compound selectivity may expand safety windows and minimize non-selective or unwanted side effects in disorders where either no specific treatment is available or current pharmaceuticals are causing severe aversive effects. Of note, next to modulation of intracellular signaling cascades involved in neuroplasticity and neuroprotection, PDE inhibitors affect inflammatory and apoptotic cascades, and increase blood-flow and glucose metabolism. More detailed understanding and description of the different isoforms and splice variants in these processes and their involvement in neuropsychiatric disorders related to corticostriatal and hippocampal dysfunction will additionally help to increase efficacy in future studies.
Additionally, alternative treatment regimen strategies involving PDEs should be considered. Most clinical efficacy studies implement acute treatments while patients mostly receive chronic treatment. Acute treatment mainly involves short-term neuroplasticity, while chronic treatment also induces long-term neuroplasticity and neuroprotection for better therapeutic outcome. Next to altering the treatment regimen, new developmental approaches have to be explored. In addition to the development of more selective inhibitors as mentioned above, a combination of sub-optimal doses of PDE inhibitors may also create enhanced efficacy while reducing or even preventing unwanted aversive effects (Bollen et al., 2015) , especially relevant for disorders characterized by a less localized treatment site like immune and inflammatory CNS disorders. By combining two different subtype-specific inhibitors, additive and synergistic effects are induced. For example, dual-inhibitors have recently been developed for the same purpose, like PDE3/4 inhibitors (Banner and Press, 2009 ) and PDE4/7 inhibitors (Castano et al., 2009) . Another strategy is the use of allosteric modulators (Burgin et al., 2010) or novel signalosome disruptors (Maurice et al., 2014) , that may improve efficacy and reduce adverse effects by increasing specificity.
Finally, more basic translational aspects should be considered which may be responsible for the failure of positive findings in animals to translate to humans. For instance, model and test validity. Models that are being used in animal experiments may have poor validity. These validities relate to the deficit model that reflects a disease model and the test model in which the behavior is interpreted . Other points of consideration are dosing and pharmacokinetics. CNS drugs typically show an inverted U-shaped dose-response curve, meaning that only a specific dose range leads to a beneficial effect on cognition. Especially, when the effective dose range is very narrow in animal studies, it will be difficult to titrate an effective dose for human studies. Moreover, side effects can be found at different doses across species with the consequence that the therapeutic window of drugs can be different for animals and humans. Pharmacodynamics and -kinetics are also different between species for most pharmaceuticals. For example, PDE inhibitors have a short half-life in animals (Krause and Kuhne, 1988; Rutten et al., 2007) , whereas in humans the half-life of PDE inhibitors is generally extended (Chaumais et al., 2013) . In addition, the absorption and brain penetration occur at a much faster rate in small experimental animals when compared to humans (Andes and Craig, 2002) . Another major contributing factor is sex-differences. In 1993 the NIH mandated the inclusion of woman in clinical trials, while most preclinical research is still biased towards the use of male animals only (Beery and Zucker, 2011) . Underrepresentation of females in preclinical testing compromises our understanding of female biology. The underrepresentation is especially surprising as several disorders, in which the potential use of PDE inhibitors is investigated, like depression, show a higher prevalence in woman. Finally, housing conditions of experimental animals have shown to affect study outcome (Akkerman et al., 2014) . It has been suggested that standard housed animals may not be valid test models for the evaluation of cognition enhancing drugs due to impoverished brains which results in many false positive findings of drugs, i.e. drugs will work in animals but not in humans (Gurwitz, 2001; Lynch and Gall, 2013) .
Conclusion
It can be concluded that, based on preclinical studies, PDEs seem to be an interesting and promising target for treatment of dysfunctions in neuropsychiatric disorders with the corticostriatal or hippocampal circuits as their neurobiological basis. However, the overwhelming positive preclinical findings could not yet be translated into clinical efficacy. The broad range of inhibitors, disorders and biological functions investigated in clinical trials can be reduced to effects of PDE inhibitors on cyclic nucleotide pools in striatal and hippocampal neurons. For the striatum, cAMP is considered the main player with an additional facilitating role for cGMP. In the hippocampus, both cyclic nucleotides play a more prominent role, although here a main function for cAMP has been suggested as well (Bollen et al., 2014) . With the failure of several clinical trials for corticostriatal disorders including schizophrenia and Huntington's disease, the future for PDE inhibitors for the treatment of corticostriatal disorders is highly uncertain. For hippocampal disorders, first results of Alzheimer's disease trials with PDE3, PDE4 and PDE9 inhibitors have been presented and appear promising. As a result, the future looks more optimistic for PDEs and their cyclic nucleotides as therapeutic target in hippocampal disorders.
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